KR20060008051A - Process for preparation of chiral 4-hydroxy-2-piperidinone - Google Patents

Process for preparation of chiral 4-hydroxy-2-piperidinone Download PDF

Info

Publication number
KR20060008051A
KR20060008051A KR1020040057706A KR20040057706A KR20060008051A KR 20060008051 A KR20060008051 A KR 20060008051A KR 1020040057706 A KR1020040057706 A KR 1020040057706A KR 20040057706 A KR20040057706 A KR 20040057706A KR 20060008051 A KR20060008051 A KR 20060008051A
Authority
KR
South Korea
Prior art keywords
formula
hydroxy
dichloro
bis
binafthyl
Prior art date
Application number
KR1020040057706A
Other languages
Korean (ko)
Other versions
KR100574343B1 (en
Inventor
김문환
안방글
안승호
Original Assignee
한국화학연구원
한국유나이티드제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국화학연구원, 한국유나이티드제약 주식회사 filed Critical 한국화학연구원
Priority to KR1020040057706A priority Critical patent/KR100574343B1/en
Publication of KR20060008051A publication Critical patent/KR20060008051A/en
Application granted granted Critical
Publication of KR100574343B1 publication Critical patent/KR100574343B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 입체선택적 4-하이드록시-2-피페리디논의 신규하고 효율적인 제조방법에 관한 것으로, 본 발명에 따라 질소가 이중치환된 베타케토 펜탄산 유도체를 루테늄 촉매하에 고압 수소화 반응시켜 얻어진 하이드록시 에스터를 산촉매하에 1차 탈보호 반응시킨 후 고리화 반응시키는 단계를 포함하는 4-하이드록시-2-피페리디논의 제조방법은 경제적이면서도 입체선택성 및 반응수율이 우수하므로 고지혈증 치료제, 항암제, 항생제 및 항 바이러스제를 포함하는 여러 약제의 개발에 유용하게 활용될 수 있다.The present invention relates to a novel and efficient process for the preparation of stereoselective 4-hydroxy-2-piperidinone, wherein a hydroxy ester obtained by high-pressure hydrogenation of a nitrogen-substituted betaketopentanoic acid derivative under ruthenium catalyst according to the present invention The method for preparing 4-hydroxy-2-piperidinone, which comprises a step of first deprotection reaction under an acid catalyst and a cyclization reaction, is economical and has excellent stereoselectivity and reaction yield, thereby treating hyperlipidemia, anticancer agents, antibiotics, and antiviral agents. It can be usefully used in the development of a number of drugs, including.

Description

입체선택적 4-하이드록시-2-피페리디논의 제조방법{PROCESS FOR PREPARATION OF CHIRAL 4-HYDROXY-2-PIPERIDINONE}Process for producing stereoselective 4-hydroxy-2-piperidinone {PROCESS FOR PREPARATION OF CHIRAL 4-HYDROXY-2-PIPERIDINONE}

본 발명은 고지혈증 치료제, 항생제, 항바이러스제 및 항암제를 비롯한 여러 약제의 핵심 중간체로 사용되는 4-하이드록시-2-피페리디논을 입체선택적으로 제조하는 방법에 관한 것이다.The present invention relates to a method for the stereoselective preparation of 4-hydroxy-2-piperidinone for use as a key intermediate of several drugs, including hyperlipidemia, antibiotics, antivirals and anticancer agents.

하기 화학식 1a 및 1b로 표시되는 4-하이드록시-2-피페리디논은 아토르바스타틴, 시스-트랜스-4-하이드록시 피페콜릭산, 알칼로이드 SS 20,846A, 강력한 HIV 저해제인 팔리나비르, 항암제인 CHIR 200,131 유도체 등의 핵심 중간체로 그 수요가 크다. 4-hydroxy-2-piperidinone represented by the following formulas (1a) and (1b) is atorvastatin, cis-trans-4-hydroxy pipecolic acid, alkaloids SS 20,846A, powerful HIV inhibitor palinavir, anticancer agent CHIR 200,131 Key intermediates such as derivatives are in great demand.

Figure 112004032846012-PAT00001
Figure 112004032846012-PAT00001

Figure 112004032846012-PAT00002
Figure 112004032846012-PAT00002

상기 식에서, Q는 수소, C1-4 직쇄 또는 분지쇄 알킬 또는 벤질을 나타낸다.Wherein Q represents hydrogen, C 1-4 straight or branched alkyl or benzyl.

상기 식 1a 및 1b의 화합물에 대한 기존 제조방법들을 살펴보면, 하기 반응식 1에 나타낸 바와 같이, 1) 치환된 글루타로니트릴로부터 몇 단계의 효소반응 및 화학반응을 거쳐 합성하거나(참고문헌: 저자 Mei-Xiang Wang 등, Tetrahedron Lett, 41, 8549-8552, 2000; 저자 Timothy Beard 등, Tetrahedron Asymmetry, 4, 1085-1104, 1993 등), 2) 에피클로로히드린으로부터 화학적 및 효소화학적 방법에 의해 합성하거나(참고문헌: JACS, 122, 168-169, 2000; US 4,705,572), 3) 피페리디논을 효소 반응시켜(참고문헌 JOC 2002. 67. 7869-7871)합성하였다.Looking at the existing preparation methods for the compounds of Formula 1a and 1b, as shown in Scheme 1, 1) synthesized from substituted glutaronitrile through several steps of enzymatic and chemical reaction (Reference: Author Mei- Xiang Wang et al., Tetrahedron Lett , 41, 8549-8552, 2000; author Timothy Beard et al., Tetrahedron Asymmetry , 4, 1085-1104, 1993, etc.), 2) synthesized from epichlorohydrin by chemical and enzymatic methods ( REFERENCES: JACS, 122, 168-169, 2000; US 4,705, 572), 3) Piperidinone was synthesized by enzymatic reaction (Reference JOC 2002. 67. 7869-7871).

Figure 112004032846012-PAT00003
Figure 112004032846012-PAT00003

그러나, 상기 반응식 1에 따른 반응들은 반응조건이 까다롭고 입체선택성이 낮으며 비경제적이다.However, the reactions according to Scheme 1 have difficult reaction conditions, low stereoselectivity, and are uneconomical.

따라서, 본 발명의 목적은 입체선택적인 4-하이드록시-2-피페리디논의 보다 효율적인 제조방법을 제공하는 것이다.
It is therefore an object of the present invention to provide a more efficient process for the preparation of stereoselective 4-hydroxy-2-piperidinone.

상기 목적을 달성하기 위해 본 발명에서는, 하기 화학식 2의 질소가 이중치환된 베타케토 펜탄산 에스터를 루테늄 촉매 존재하에서 고압수소화 반응시켜 높은 입체선택성을 갖는 하기 화학식 3a 또는 3b의 질소가 이중치환된 베타 하이드록시 펜탄산 에스터를 합성한 후, 이를 탈보호 반응 및 고리화 반응시키는 단계를 포함하는, 질소가 치환된 높은 입체선택성을 갖는 하기 화학식 1a 또는 1b의 4-하이드록시-피페리디논의 제조방법을 제공한다.In order to achieve the above object, in the present invention, the beta keto pentanoic acid ester of the following formula (2) is a bi-substituted beta keto pentanoic acid ester in the presence of a ruthenium catalyst to a high pressure hydrogenation of the nitrogen of the formula (3a) Synthesis of hydroxy pentanoic acid ester, followed by a deprotection reaction and a cyclization reaction, a method for preparing 4-hydroxy-piperidinone of formula 1a or 1b having nitrogen-substituted high stereoselectivity to provide.

<화학식 1a><Formula 1a>

Figure 112004032846012-PAT00004
Figure 112004032846012-PAT00004

<화학식 1b><Formula 1b>

Figure 112004032846012-PAT00005
Figure 112004032846012-PAT00005

Figure 112004032846012-PAT00006
Figure 112004032846012-PAT00006

Figure 112004032846012-PAT00007
Figure 112004032846012-PAT00007

Figure 112004032846012-PAT00008
Figure 112004032846012-PAT00008

상기 식에서,Where

P 및 P1는 각각 독립적으로 벤질, 벤질옥시카보닐, t-부틸옥시카보닐, 벤조일, 아세틸 등을 나타내며, P and P 1 each independently represent benzyl, benzyloxycarbonyl, t-butyloxycarbonyl, benzoyl, acetyl, and the like,

R은 메틸, 에틸, 프로필, 부틸, t-부틸, 아이소프로필 등의 탄소수 1 내지 4의 선 형 또는 분지형 알킬기를 나타내고, R represents a linear or branched alkyl group having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, butyl, t-butyl, isopropyl,

Q는 수소, 탄소수 1 내지 4의 선형 또는 분지형 알킬 또는 벤질을 나타낸다.Q represents hydrogen, linear or branched alkyl or benzyl having 1 to 4 carbon atoms.

이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명에 따른 방법은 하기 반응식 2와 같이 나타낼 수 있다.The method according to the invention can be represented as in Scheme 2 below.

Figure 112004032846012-PAT00009
Figure 112004032846012-PAT00009

상기 반응식에서, P, P1, R 및 Q는 상기 화학식 정의에서 기재한 바와 같다.In the above scheme, P, P 1 , R and Q are as described in the above formula definition.

상기 반응식 2는 보다 구체적으로 하기 반응식 2a 내지 2c로 나타낼 수 있다.Reaction Scheme 2 may be represented by Reaction Schemes 2a to 2c more specifically.

Figure 112004032846012-PAT00010
Figure 112004032846012-PAT00010

Figure 112004032846012-PAT00011
Figure 112004032846012-PAT00011

Figure 112004032846012-PAT00012
Figure 112004032846012-PAT00012

상기 반응식에서, P, P1, R 및 Q는 상기 화학식 정의에서 기재한 바와 같다.In the above scheme, P, P 1 , R and Q are as described in the above formula definition.

상기 반응식 2에서 출발물질로 사용된 화학식 2의 질소-이중치환된 베타 케토 펜탄산 에스터는 바람직하게는, 본원과 동일 출원인의 한국특허출원 제2003-51360호와 같은 방법으로 합성할 수 있으며, 구체적으로는, 메탄올, 에탄올, 아이소프로판올, 부탄올 등과 같은 알콜, 테트라하이드로퓨란, 아세토나이트릴, 디메틸포름아미드 등과 같은 유기용매 중에서 루테늄 촉매 하에서 30~100기압의 압력으로 수소화 반응을 시켜 얻을 수 있다.Nitrogen-disubstituted beta ketopentanoic acid ester of Chemical Formula 2 used as starting material in Scheme 2 may be synthesized in the same manner as in Korean Patent Application No. 2003-51360 of the same applicant as the present application. As an organic solvent such as alcohol such as methanol, ethanol, isopropanol, butanol, tetrahydrofuran, acetonitrile, dimethylformamide or the like, it can be obtained by hydrogenation reaction under a ruthenium catalyst at a pressure of 30 to 100 atm.

예를 들어, 상기 반응식 2a 및 2b에 따르면, 고압 수소화 반응으로 얻어진 질소가 이중치환된 베타 하이드록시 펜탄산 에스테르를 산 존재하에 t-부틸기를 통상의 방법으로 탈보호 반응시킨 후, 염기 존재 하에서 고리화 반응시키면, 90%이상 좋은 수율로 N-벤질-4-하이드록시-피페리딘-2-온을 얻을 수 있다.For example, according to Schemes 2a and 2b, after nitrogen-desubstituted beta hydroxypentanoic acid ester obtained by the high-pressure hydrogenation reaction is deprotected by a conventional method in t-butyl group in the presence of an acid, the ring is present in the presence of a base. When the reaction is carried out, N-benzyl-4-hydroxy-piperidin-2-one can be obtained in a good yield of 90% or more.

또한, 예를 들어, 상기 반응식 2c에서와 같이, 질소가 벤질과 벤질옥시 카르보닐기로 치환된 베타하이드록시 펜탄산 에스테르를 상기 반응식 2a 또는 2b에서와 같이 고압수소화 반응시킨 후, 이를 바로 탈보호 및 고리화 반응시키지 않고, 5% Pd/C 존재하에 상압에서 짧은시간(예를 들어 30분)동안 수소화 반응시키면 벤질옥시카보닐기가 제거된 물질이 쉽게 얻어지며, 이를 염기로 처리하여 고리화시키면 N-벤질-4-하이드록시-피페리딘-2-온이 얻어지고, 이를 다시 장시간(예를 들면 10시간) 수소화 반응시키면 N-벤질이 제거된 4-하이드록시-피페리딘-2-온을 좋은 수율로 얻을 수 있다. 이때 상기 고리화 반응과 후속 수소화반응은 순서를 바꾸어 수행할 수도 있다.Further, for example, as shown in Scheme 2c, betahydroxy pentanic acid ester in which nitrogen is substituted with benzyl and benzyloxy carbonyl group is subjected to high-pressure hydrogenation as in Scheme 2a or 2b, and then deprotection and ring Hydrogenation of the benzyloxycarbonyl group with a short time (e.g., 30 minutes) at normal pressure in the presence of 5% Pd / C without the polymerization reaction yields a substance free of benzyloxycarbonyl groups. Benzyl-4-hydroxy-piperidin-2-one is obtained, which is then hydrogenated again for a long time (e.g., 10 hours) to form 4-hydroxy-piperidin-2-one with N-benzyl removed. Good yield can be obtained. At this time, the cyclization reaction and the subsequent hydrogenation reaction may be carried out by changing the order.

상기 수소화 반응에 사용될 수 있는 루테늄 촉매의 예로는 (R)Ru2Cl4(BINAP)NEt3(디클로로[R(+)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄트리에틸아민),(S)Ru2Cl4(BINAP)NEt3(디클로로[S(-)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄트리에틸아민), (R)Ru2Cl2(BINAP)2(디클로로[R(+)-2,2'-비스(디페놀닐스피노)-1,1'-비나프틸]루테늄), (S)Ru2Cl2(BINAP)2(디클로로[S(-)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄), (R)Ru2Cl4(Tol-BINAP)2NEt3 (디클로로[R(+)-2,2'-톨루일-비스(디페닐포스피노)-1,1'-비나프틸]루테늄트리에틸아민), (S)Ru2Cl4(Tol-BINAP)2NEt3(디클로로[S(-)-2,2'-톨루일-비스(디페닐스피노)-1,1'-비나프틸]루테늄트리에틸아민) 등이 있다. Examples of ruthenium catalysts that can be used in the hydrogenation reaction include (R) Ru 2 Cl 4 (BINAP) NEt 3 (dichloro [R (+)-2,2'-bis (diphenylphosphino) -1,1'- Vinaphthyl] rutheniumtriethylamine) , (S) Ru 2 Cl 4 (BINAP) NEt 3 (dichloro [S (-)-2,2'-bis (diphenylphosphino) -1,1'-binaf Tyl] rutheniumtriethylamine) , (R) Ru 2 Cl 2 (BINAP) 2 (dichloro [R (+)-2,2'-bis (diphenolylspino) -1,1'-binafthyl] ruthenium ), (S) Ru 2 Cl 2 (BINAP) 2 (dichloro [S (-)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] ruthenium), (R) Ru 2 Cl 4 (Tol-BINAP) 2 NEt 3 (dichloro [R (+)-2,2'-toluyl-bis (diphenylphosphino) -1,1'-binafthyl] rutheniumtriethylamine) , And (S) Ru 2 Cl 4 (Tol-BINAP) 2 NEt 3 (dichloro [S (-)-2,2'-toluyl-bis (diphenylspino) -1,1'-binafthyl] rutheniumtriethyl Amines).

상기 수소화 반응에서의 온도는 0℃~100℃ 범위가 적합하고, 약 30℃가 바람직하다. 바람직한 용매로는 테트라히드로푸란, 아세트나이트릴, 디메틸포름아미드, 디메틸에테르, 에틸아세테이트, 아세톤, 클로로포름, 메탄올, 에탄올, 아이소프로판올, 부탄올 등과 같은 유기용매를 사용할 수 있다.As for the temperature in the said hydrogenation reaction, the range of 0 degreeC-100 degreeC is suitable, and about 30 degreeC is preferable. Preferred solvents include organic solvents such as tetrahydrofuran, acetonitrile, dimethylformamide, dimethyl ether, ethyl acetate, acetone, chloroform, methanol, ethanol, isopropanol, butanol and the like.

상기 탈보호 반응에서 사용되는 산으로는 염산 가스를 알코올에 포화시킨 용액이나 톨루엔설폰산, 옥살산, 트리플루오로아세트산, 6N HCl, 기타 무기산을 사용할 수 있으며, 상기 고리화 반응에 사용가능한 염기로는 탄산칼륨, 탄산칼슘, 탄산 나트륨, 수소화나트륨, 3급 부톡시화칼륨, 메톡시화칼륨, 수산화나트륨, 수산화칼륨 등의 무기염류와 트리에틸아민, 디이소프로필에틸아민, 1,8-디아자 비시클로 [5,4,0]-7-운데센(DBU) 등의 유기 염류가 있다.As the acid used in the deprotection reaction, a solution of saturated hydrochloric acid gas in alcohol, toluenesulfonic acid, oxalic acid, trifluoroacetic acid, 6N HCl, and other inorganic acids may be used. Inorganic salts such as potassium carbonate, calcium carbonate, sodium carbonate, sodium hydride, tert-butoxide, potassium methoxide, sodium hydroxide and potassium hydroxide, triethylamine, diisopropylethylamine, 1,8-diazabicyclo Organic salts such as [5,4,0] -7-undecene (DBU).

이하 본 발명을 실시 예에 의거하여 자세히 설명하기로 하며 이들 실시 예는 본 발명을 예시하는 것일 뿐 본 발명이 이들 실시예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, and these Examples are merely illustrative of the present invention, and the present invention is not limited to these Examples.

제조예 1: 5-(벤질,t-부톡시카보닐아미노)-3-옥소-펜탄산 에틸 에스터의 합성Preparation Example 1 Synthesis of 5- (benzyl, t-butoxycarbonylamino) -3-oxo-pentanoic acid ethyl ester

1L 반응기에 3-(벤질-t-부톡시카보닐아미노)-프로온산 20g (0.07mol)과 아세트니트릴 400mL를 넣고 질소하에서 15분간 교반하고, 그 후 1.1'-카보닐 디이미다졸 13g (0.084mol)을 넣고 30분간 더 교반한 후 온도를 10℃로 낮추고 포타슘말로네이트 에틸 에스터 18.4g (0.105mol)과 마그네슘 클로라이드 7.5g (0.077mol)을 각각 첨가하고 1시간 교반하였다. 그 후 58℃로 2시간 더 교반한뒤 반응이 완료되면, 실온으로 식히고 감압 증류 하여 용매를 제거한 후 에틸아세테이트와 6N 염산용액으로 pH=4로 조절하여 추출한 후 유기층은 무수황산 마그네슘으로 건조시킨 뒤 감압 농축하여 노란색 오일 21g (85%)을 얻었다.  20 g (0.07 mol) of 3- (benzyl-t-butoxycarbonylamino) -propionic acid and 400 mL of acetonitrile were added to a 1 L reactor, followed by stirring under nitrogen for 15 minutes, followed by 13 g of 1.1'-carbonyl diimidazole (0.084). mol) and further stirred for 30 minutes, the temperature was lowered to 10 ℃, 18.4 g (0.105 mol) of potassium malonate ethyl ester and 7.5 g (0.077 mol) of magnesium chloride were added and stirred for 1 hour. After stirring for 2 hours at 58 ° C., the reaction was completed. After cooling to room temperature and distilling under reduced pressure to remove the solvent, the mixture was extracted and adjusted to pH = 4 with ethyl acetate and 6N hydrochloric acid solution, and the organic layer was dried over anhydrous magnesium sulfate. Concentration under reduced pressure afforded 21 g (85%) of a yellow oil.

1H NMR(CDCl3, ppm): δ 7.54-7.23(m, 5H), 4.44(s, 2H), 4.17(q, 2H), 3.45-3,36(m, 4H), 2.81-2.71(m, 2H), 1.45(s, 9H), 1.28(t, 3H) 1 H NMR (CDCl 3 , ppm): δ 7.54-7.23 (m, 5H), 4.44 (s, 2H), 4.17 (q, 2H), 3.45-3,36 (m, 4H), 2.81-2.71 (m , 2H), 1.45 (s, 9H), 1.28 (t, 3H)

제조예 2: 5-(벤질, 벤질옥시카보닐아미노)-3-옥소-펜탄산 에틸에스터의 합 성Preparation Example 2 Synthesis of 5- (benzyl, benzyloxycarbonylamino) -3-oxo-pentanoic acid ethyl ester

1L 반응기에 3-(벤질, 벤질옥시카보닐아미노)-프로피온산 28g (0.09mol)과 아세토니트릴 500mL를 넣고 질소하에서 15분간 교반하고, 그 후 1,1'-카르보닐디이미다졸 15.9g (0.108mol)을 넣고 30분간 더 교반한 뒤, 온도를 10℃로 낮추고 포타슘 말로네이트 에틸에스터 22.7g과 마그네슘 클로라이드 9.4g을 각각 첨가하고 1시간 교반하였다. 그 후 50℃로 2시간 더 교반한 뒤 반응이 완료되면, 실온으로 식히고 감압증류하여 용매는 제거한 후, 에틸아세테이트와 6N 염산용액으로 pH=4로 조절하여 추출한 후 유기층은 무수황산 마그네슘으로 건조시킨뒤, 감압농축하여 노란색 오일 29.3g (85%)을 얻었다.  Into a 1 L reactor, 28 g (0.09 mol) of 3- (benzyl, benzyloxycarbonylamino) -propionic acid and 500 mL of acetonitrile were stirred under nitrogen for 15 minutes, after which 15.9 g of 1,1'-carbonyldiimidazole (0.108) was added. mol) and further stirred for 30 minutes, the temperature was lowered to 10 ℃, 22.7g of potassium malonate ethyl ester and 9.4g of magnesium chloride were added and stirred for 1 hour. After further stirring at 50 ° C. for 2 hours, when the reaction was completed, the reaction mixture was cooled to room temperature, distilled under reduced pressure, and the solvent was removed. The mixture was extracted with ethyl acetate and 6N hydrochloric acid, adjusted to pH = 4, and the organic layer was dried over anhydrous magnesium sulfate. Then, the mixture was concentrated under reduced pressure to give 29.3 g (85%) of a yellow oil.

1H NMR(CDCl3, ppm): δ 7.36-7.25(m, 5H), 5.16(s, 2H), 4.51(s, 2H), 4.14(q, 4H), 2.84-2.70(m, 2H), 1.24(t, 3H) 1 H NMR (CDCl 3 , ppm): δ 7.36-7.25 (m, 5H), 5.16 (s, 2H), 4.51 (s, 2H), 4.14 (q, 4H), 2.84-2.70 (m, 2H), 1.24 (t, 3 H)

제조예 3: 5-(벤질, 벤질옥시카보닐아미노)-3(R)-하이드록시 펜탄산 에틸에스터의 합성Preparation Example 3 Synthesis of 5- (benzyl, benzyloxycarbonylamino) -3 (R) -hydroxypentanoic acid ethyl ester

제조예 2에서 얻은 5-(벤질, 벤질옥시카보닐아미노)-3-옥소-펜탄산 에틸에스터 20g (0.052mol)과 디클로로[R(+)-2,2'-비스(디페놀포스피노)-1,1'-비나프틸]루테늄 10mg을 무수에탄올 100mL에 넣고 고압 수소 반응기에서 70기압으로 상온에서 24시간 동안 반응시켰다. 반응 완료 후 감압증류하여 에탄올을 제거하고 에틸아세트와 물로 추출한 뒤 유기층을 무수 황산 마그네슘으로 건조시킨 후 농축하고 실리 카겔 컬럼 크로마토그래피 (헥산/에틸아세테이트 =2/1)로 분리 정제하여 노란색오일 17.2g (85% , ee98∼99%)을 얻었다.20 g (0.052 mol) of 5- (benzyl, benzyloxycarbonylamino) -3-oxo-pentanoic acid ethyl ester obtained in Preparation Example 2 and dichloro [R (+)-2,2'-bis (diphenolphosphino) 10 mg of -1,1'-binafthyl] ruthenium was added to 100 mL of anhydrous ethanol and reacted at room temperature at 70 atm in a high pressure hydrogen reactor for 24 hours. After completion of the reaction, the mixture was distilled under reduced pressure to remove ethanol, extracted with ethyl acetate and water, the organic layer was dried over anhydrous magnesium sulfate, concentrated, and separated and purified by silica gel column chromatography (hexane / ethyl acetate = 2/1) to give 17.2 g of yellow oil. (85%, ee98-99%) were obtained.

1H NMR(CDCl3, ppm): δ 7.36-7.18(m, 5H), 5.18(s, 2H), 4.58-4.37(m, 2H), 4.14(q, 2H), 4.09-3.90(m, 1H), 3.63(br, 1H), 3.39-3.01(m, 2H) 2.47-2.36(m, 2H) 1.79-1.45(m, 2H), 1.25(t, 3H) 1 H NMR (CDCl 3 , ppm): δ 7.36-7.18 (m, 5H), 5.18 (s, 2H), 4.58-4.37 (m, 2H), 4.14 (q, 2H), 4.09-3.90 (m, 1H ), 3.63 (br, 1H), 3.39-3.01 (m, 2H) 2.47-2.36 (m, 2H) 1.79-1.45 (m, 2H), 1.25 (t, 3H)

HPLC: 컬럼: Chiralcel-OD, 이동상: 헥산:이소프로판올=90:10, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 21.97분HPLC: column: Chiralcel-OD, mobile phase: hexane: isopropanol = 90:10, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 21.97 minutes

제조예 4: 5-(벤질,벤질 옥시카보닐아미노)-3-(S)-하이드록시 펜탄산 에틸에스터의 합성Preparation Example 4 Synthesis of 5- (benzyl, benzyloxycarbonylamino) -3- (S) -hydroxypentanoic acid ethyl ester

상기 제조예 3과 동일한 방법으로 수행하였으며 루테늄 촉매는 디클로로[S(-)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄을 사용하였다. (수율 89%, ee 98%이상)The ruthenium catalyst was used in the same manner as in Preparation Example 3, and dichloro [S (-)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] ruthenium was used. (Yield 89%, ee 98% or more)

1H NMR(CDCl3, ppm): δ 7.36-7.18(m, 5H), 5.18(s, 2H), 4.58-4.37(m, 2H), 4.14(q, 2H), 4.09-3.90(m, 1H), 3.63(br, 1H), 3.39-3.01(m, 2H), 2.47-2.36(m, 2H), 1.79-1.45(m, 2H), 1.25(t, 3H) 1 H NMR (CDCl 3 , ppm): δ 7.36-7.18 (m, 5H), 5.18 (s, 2H), 4.58-4.37 (m, 2H), 4.14 (q, 2H), 4.09-3.90 (m, 1H ), 3.63 (br, 1H), 3.39-3.01 (m, 2H), 2.47-2.36 (m, 2H), 1.79-1.45 (m, 2H), 1.25 (t, 3H)

HPLC: 컬럼: Chiralcel-OD, 이동상: 헥산:이소프로판올=90:10, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 31.00분HPLC: column: Chiralcel-OD, mobile phase: hexane: isopropanol = 90: 10, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 31.00 min

제조예 5: 5-(벤질, t-부톡시카보닐아미노)-3-(R)-하이드록시산 에틸 에스터의 합성Preparation Example 5 Synthesis of 5- (benzyl, t-butoxycarbonylamino) -3- (R) -hydroxy acid ethyl ester

상기 제조예 1에서 얻은 5-(벤질, t-부톡시카보닐아미노)-3-옥소-펜탄산 에틸 에스터 10g과 디클로로[R(+)-2,2'-비스(디페놀포스피노)-1,1'-비나프틸]루테늄, 5mg을 상온에서 24시간 동안 반응시켰다. 반응 완료 후 감압 증류하여 에탄올을 제거하고 에틸아세테이트와 물로 추출한 뒤 유기층을 무수 황산 마그네슘으로 건조시킨 후 농축하고 실리카겔 컬럼 크로마토그래피(헥산/ 에틸아세테이트= 2/1)로 분리 정제하여 노란색 오일 9.1g을 얻었다.  10 g of 5- (benzyl, t-butoxycarbonylamino) -3-oxo-pentanoic acid ethyl ester and dichloro [R (+)-2,2'-bis (diphenolphosphino)-obtained in Preparation Example 1 1,1'-binafthyl] ruthenium and 5 mg were reacted at room temperature for 24 hours. After completion of the reaction, the reaction mixture was distilled under reduced pressure to remove ethanol, extracted with ethyl acetate and water, the organic layer was dried over anhydrous magnesium sulfate, concentrated, and separated and purified by silica gel column chromatography (hexane / ethyl acetate = 2/1) to give 9.1g of yellow oil. Got it.

1H NMR(CDCl3, ppm): δ 7.34-7.21(m, 5H), 4.58-4.20(m, 2H), 4.12(q, 2H), 4.02-3.92(m, 1H), 3.70(br, 1H), 3.27-2.98(m, 2H), 2.55-2.38(m, 2H), 1.80-1.48(m, 2H) 1.80-1.48(m, 2H), 1.46(s, 9H), 1.26(t, 3H) 1 H NMR (CDCl 3 , ppm): δ 7.34-7.21 (m, 5H), 4.58-4.20 (m, 2H), 4.12 (q, 2H), 4.02-3.92 (m, 1H), 3.70 (br, 1H ), 3.27-2.98 (m, 2H), 2.55-2.38 (m, 2H), 1.80-1.48 (m, 2H) 1.80-1.48 (m, 2H), 1.46 (s, 9H), 1.26 (t, 3H)

HPLC: 컬럼: Chiralcel-OD, 이동상: 헥산:이소프로판올=90:10, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 11.78분HPLC: column: Chiralcel-OD, mobile phase: hexane: isopropanol = 90:10, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 11.78 minutes

제조예 6: 5-(벤질, t-부톡시카보닐아미노)-3-(S)-하이드록시산 에틸 에스터Preparation Example 6 5- (Benzyl, t-butoxycarbonylamino) -3- (S) -hydroxy acid ethyl ester

상기 제조예 5와 동일한 방법으로 수행하였으며 루테늄 촉매는 디클로로[S(-)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄을 사용하였다. (수율: 90%, ee 98% up)The ruthenium catalyst was used in the same manner as in Preparation Example 5, and dichloro [S (-)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] ruthenium was used. (Yield: 90%, ee 98% up)

1H NMR(CDCl3, ppm): δ 7.34-7.21(m, 5H), 4.58-4.20(m, 2H), 4.58-4.20(m, 2H), 4.12(q, 2H), 4.02-3.92(m, 1H), 3.70(br, 1H), 3.27-2.98(m, 2H), 2.55-2.38(m, 2H) 1.80-1.48(m, 2H), 1.46(s, 9H), 1.26(t, 3H) 1 H NMR (CDCl 3 , ppm): δ 7.34-7.21 (m, 5H), 4.58-4.20 (m, 2H), 4.58-4.20 (m, 2H), 4.12 (q, 2H), 4.02-3.92 (m , 1H), 3.70 (br, 1H), 3.27-2.98 (m, 2H), 2.55-2.38 (m, 2H) 1.80-1.48 (m, 2H), 1.46 (s, 9H), 1.26 (t, 3H)

HPLC: 컬럼: Chiralcel-OD, 이동상: 헥산:이소프로판올=90:10, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 16.11분HPLC: column: Chiralcel-OD, mobile phase: hexane: isopropanol = 90:10, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 16.11 minutes

제조예 7 내지 10Preparation Examples 7 to 10

상기 제조예 3 내지 6에 따른 반응공정에 있어서 Ru 촉매로서 Ru BINAPCl2 ·Et3N를 사용하여 에스터 물질들을 합성하였으며 이를 하기 표 1에 정리하여 나타 내었다.Ester materials were synthesized using Ru BINAPCl 2 · Et 3 N as the Ru catalyst in the reaction process according to Preparation Examples 3 to 6, which are summarized in Table 1 below.

Figure 112004032846012-PAT00013
Figure 112004032846012-PAT00013

실시예 1: N-벤질-4-(R)-하이드록시 피페리딘-2-온의 합성Example 1: Synthesis of N-benzyl-4- (R) -hydroxy piperidin-2-one

제조예 5에서 얻은 5-(벤질,t-부톡시 카보닐아미노)-3-(R)-하이드록시 펜탄산 에틸에스터 5g을 100ml 반응기에 넣고 에탄올 50ml를 넣은 다음 10% HCl/MeOH 10ml를 가한 후 상온에서 5시간 교반시켰다. t-부틸기가 제거된 것을 TLC 상으로 확인한 후 용매를 감압 증류하여 5-벤질 아미노-3(R)-하이드록시산 에틸 에스터 하이드로클로라이드를 얻은 후, 이를 정제하지 않고 에탄올 50mL에 넣고 소디움 에톡사이드 1.5g을 넣고 2시간 환류시켰다. 용매를 감압증류한 후 Hex:EA=1:1로 실리카 겔 컬럼 크로마토그래피하여 목적 화합물 3g을 얻었다. (수율 85%)5 g of 5- (benzyl, t-butoxycarbonylamino) -3- (R) -hydroxypentanoic acid ethyl ester obtained in Preparation Example 5 were added to a 100 ml reactor, 50 ml of ethanol was added, and 10 ml of 10% HCl / MeOH was added thereto. After stirring at room temperature for 5 hours. After confirming that the t-butyl group was removed by TLC, the solvent was distilled under reduced pressure to obtain 5-benzylamino-3 (R) -hydroxy acid ethyl ester hydrochloride, which was placed in 50 mL of ethanol without purification and sodium ethoxide 1.5 g was added and refluxed for 2 hours. After distilling the solvent under reduced pressure, silica gel column chromatography was performed with Hex: EA = 1: 1 to obtain 3 g of the target compound. (Yield 85%)

1H NMR(CDCl3, ppm): δ 7.34-7.22(m, 5H), 4.57(dd, 2H), 4.18-4.15(m, 1H), 3.62-3.45(br, 1H), 3.43-3.38(m, 1H), 3.15-3.10(m, 1H), 2.69(dd, 1H) 2.48(dd, 1H), 1.96-1.91(m, 1H), 1.85-1.79(m, 1H) 1 H NMR (CDCl 3 , ppm): δ 7.34-7.22 (m, 5H), 4.57 (dd, 2H), 4.18-4.15 (m, 1H), 3.62-3.45 (br, 1H), 3.43-3.38 (m , 1H), 3.15-3.10 (m, 1H), 2.69 (dd, 1H) 2.48 (dd, 1H), 1.96-1.91 (m, 1H), 1.85-1.79 (m, 1H)

HPLC: 컬럼: Chiral PAK AS, 이동상: 헥산:이소프로판올=75:25, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 12.12분HPLC: column: Chiral PAK AS, mobile phase: hexane: isopropanol = 75: 25, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 12.12 minutes

실시예 2: N-벤질-4-(S)-하이드록시 피페리딘-2-온의 합성 Example 2: Synthesis of N-benzyl-4- (S) -hydroxy piperidin-2-one

제조예 6에서 얻은 5-(벤질,t-부톡시카보닐아미노)-3-(S)-하이드록시 에틸에스터 5g을 100mL 반응기에 넣고 에탄올 50mL을 넣은 다음 10% HCl/MeOH 10mL을 가한 후 상온에서 5시간 교반시켰다. t-부틸기가 제거된 것을 TLC상으로 확인한 후 용매를 감압 증류하여 5-벤질아미노-3-(S)-하이드록시산 에틸에스터 하이드로 클로라이드를 얻은 후, 이를 정제하지 않고 에탄을 50mL에 넣고 소디움 에톡사이드 1.45g을 넣고 2시간 동안 환류시켰다. 용매를 감압 증류한 후 Hex:EA=1:1로 실리카겔 컬럼 크로마토그래피하면 원하는 목적 화합물을 3.1g을 얻었다.5 g of 5- (benzyl, t-butoxycarbonylamino) -3- (S) -hydroxyethyl ester obtained in Preparation Example 6 were added to a 100 mL reactor, 50 mL of ethanol was added, and 10 mL of 10% HCl / MeOH was added thereto. Stirred for 5 hours. After confirming that the t-butyl group was removed by TLC, the solvent was distilled under reduced pressure to obtain 5-benzylamino-3- (S) -hydroxy acid ethyl ester hydrochloride, which was then purified without addition of ethane to 50 mL of sodium ethoxylate. Add 1.45 g of side and reflux for 2 hours. After distilling off the solvent under reduced pressure, silica gel column chromatography with Hex: EA = 1: 1 gave 3.1 g of the desired compound.

1H NMR(CDCl3, ppm): δ 7.34-7.22(m, 5H), 4.57(dd, 2H), 4.18-4.15(m, 1H), 3.62-3.45(br, 1H), 3.43-3.38(m, 1H), 3.15-3.10(m, 1H), 2.69(dd, 1H) 2.48(dd, 1H), 1.96-1.91(m, 1H), 1.85-1.79(m, 1H) 1 H NMR (CDCl 3 , ppm): δ 7.34-7.22 (m, 5H), 4.57 (dd, 2H), 4.18-4.15 (m, 1H), 3.62-3.45 (br, 1H), 3.43-3.38 (m , 1H), 3.15-3.10 (m, 1H), 2.69 (dd, 1H) 2.48 (dd, 1H), 1.96-1.91 (m, 1H), 1.85-1.79 (m, 1H)

HPLC: 컬럼: Chiral PAK AS, 이동상: 헥산:이소프로판올=75:25, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 19.62분HPLC: column: Chiral PAK AS, mobile phase: hexane: isopropanol = 75: 25, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 19.62 minutes

실시예 3: N-벤질-4-(R)-하이드록시 피페리딘-2-온의 합성Example 3: Synthesis of N-benzyl-4- (R) -hydroxy piperidin-2-one

제조예 3에서 얻은 5-(벤질, 벤질옥시카보닐아미노)-3-(R)-하이드로시 펜탄산 에틸에스터 5g을 100mL 반응기에 넣고 메탄올 50mL을 넣은 다음 5% Pd/C 100mg을 넣고 수소화 반응을 상온 상압하에서 30분간 시켰다. 셀라이트를 사용하여 5% Pd/C를 여과 후, 제거한 다음 반응액에 소디움 에톡사이드를 넣고 2시간 환류시켰다. 용매를 감압 증류한 후 Hex:EA=1:1로 실리카겔 컬럼 크로마토그래피하여 목적 화합물을 2.26g 얻었다.5 g of 5- (benzyl, benzyloxycarbonylamino) -3- (R) -hydroxypentanoic acid ethyl ester obtained in Preparation Example 3 were placed in a 100 mL reactor, 50 mL of methanol was added, and 100 mg of 5% Pd / C was added. Was carried out for 30 minutes at room temperature and atmospheric pressure. 5% Pd / C was filtered off using Celite, and then sodium ethoxide was added to the reaction solution and refluxed for 2 hours. After distilling off the solvent under reduced pressure, silica gel column chromatography was performed with Hex: EA = 1: 1 to obtain 2.26 g of the title compound.

1H NMR(CDCl3, ppm): δ 7.34-7.22(m, 5H), 4.57(dd, 2H), 4.18-4.15(m, 1H), 3.62-3.45(br, 1H), 3.43-3.38(m, 1H), 3.15-3.10(m, 1H), 2.69(dd, 1H) 2.48(dd, 1H), 1.96-1.91(m, 1H), 1.85-1.79(m, 1H) 1 H NMR (CDCl 3 , ppm): δ 7.34-7.22 (m, 5H), 4.57 (dd, 2H), 4.18-4.15 (m, 1H), 3.62-3.45 (br, 1H), 3.43-3.38 (m , 1H), 3.15-3.10 (m, 1H), 2.69 (dd, 1H) 2.48 (dd, 1H), 1.96-1.91 (m, 1H), 1.85-1.79 (m, 1H)

HPLC: 컬럼: Chiral PAK AS, 이동상: 헥산:이소프로판올=75:25, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 12.12분HPLC: column: Chiral PAK AS, mobile phase: hexane: isopropanol = 75: 25, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 12.12 minutes

실시예 4: N-벤질-4-(S)-하이드록시 피페리딘-2-온의 합성Example 4: Synthesis of N-benzyl-4- (S) -hydroxy piperidin-2-one

실시예 3과 비슷한 조건으로 제조예 4에서 얻은 5-(벤질,벤질 옥시카보닐아미노)-3-(S)-하이드록시 펜탄산 에틸에스터 5g을 사용하여 반응시켜 목적 화합물 2.2g을 얻었다.Under the conditions similar to Example 3, 5 g of 5- (benzyl, benzyloxycarbonylamino) -3- (S) -hydroxypentanoic acid ethyl ester obtained in Preparation Example 4 was reacted to obtain 2.2 g of the target compound.

1H NMR(CDCl3, ppm): δ 7.34-7.22(m, 5H), 4.57(dd, 2H), 4.18-4.15(m, 1H), 3.62-3.45(br, 1H), 3.43-3.38(m, 1H), 3.15-3.10(m, 1H), 2.69(dd, 1H) 2.48(dd, 1H), 1.96-1.91(m, 1H), 1.85-1.79(m, 1H) 1 H NMR (CDCl 3 , ppm): δ 7.34-7.22 (m, 5H), 4.57 (dd, 2H), 4.18-4.15 (m, 1H), 3.62-3.45 (br, 1H), 3.43-3.38 (m , 1H), 3.15-3.10 (m, 1H), 2.69 (dd, 1H) 2.48 (dd, 1H), 1.96-1.91 (m, 1H), 1.85-1.79 (m, 1H)

HPLC: 컬럼: Chiral PAK AS, 이동상: 헥산:이소프로판올=75:25, 유속: 1mL/min, 검출 파장: 254nm, 체류시간: 19.62분HPLC: column: Chiral PAK AS, mobile phase: hexane: isopropanol = 75: 25, flow rate: 1 mL / min, detection wavelength: 254 nm, retention time: 19.62 minutes

모셔 방법에 의한 구조결정Determination of Structure by Mosher Method

상기 실시예 1 또는 3에서 얻은 N-벤질-4-(R)-하이드록시-피페리딘-2-논과 R(+)-α-메틸-α-트리플루오르메틸-페닐 아세트산을 반응시켜 에스터를 합성하였다.The ester was prepared by reacting N-benzyl-4- (R) -hydroxy-piperidine-2-non and R (+)-α-methyl-α-trifluoromethyl-phenyl acetic acid obtained in Example 1 or 3 above. Synthesized.

1H NMR(CDCl3, ppm): δ 7.18-7.47(m, 10H), 4.61(s, 2H), 4.23(brs, 1H), 3.58-3.44(m, 1H), 3.45(s, 3H), 3.19-3.13(m, 1H), 2.81-2.75(dd, J=1.85, 6.05Hz, 1H) 2.74-2.52(dd, J=1.9, 10.25Hz, 1H), 2.17-1.84(m, 1H), 1.85-1.79(m, 2H) 1 H NMR (CDCl 3 , ppm): δ 7.18-7.47 (m, 10H), 4.61 (s, 2H), 4.23 (brs, 1H), 3.58-3.44 (m, 1H), 3.45 (s, 3H), 3.19-3.13 (m, 1H), 2.81-2.75 (dd, J = 1.85, 6.05 Hz, 1H) 2.74-2.52 (dd, J = 1.9, 10.25 Hz, 1H), 2.17-1.84 (m, 1H), 1.85 -1.79 (m, 2H)

19F NMR 500MHz (CDCl3, δ ppm) 71.88 (3F, S, OCF3) 19 F NMR 500 MHz (CDCl 3 , δ ppm) 71.88 (3F, S, OCF 3 )

상기 실시예 2 또는 4에서 얻은 N-벤질-4-(S)-하이드록시-피페리딘-2-논과 R(+)-α-메틸-α-트리플루오르메틸-페닐 아세트산을 반응시켜 에스터를 합성하였다.An ester was prepared by reacting N-benzyl-4- (S) -hydroxy-piperidine-2-non and R (+)-α-methyl-α-trifluoromethyl-phenyl acetic acid obtained in Example 2 or 4 above. Synthesized.

1H NMR(CDCl3, ppm): δ 7.18-7.47(m, 10H), 4.61(s, 2H), 4.23(brs, 1H), 3.58-3.44(m, 1H), 3.45(s, 3H), 3.19-3.13(m, 1H), 2.81-2.75(dd, J=1.85, 6.05Hz, 1H) 2.74-2.52(dd, J=1.9, 10.25Hz, 1H), 2.17-1.84(m, 1H), 1.85-1.79(m, 2H) 1 H NMR (CDCl 3 , ppm): δ 7.18-7.47 (m, 10H), 4.61 (s, 2H), 4.23 (brs, 1H), 3.58-3.44 (m, 1H), 3.45 (s, 3H), 3.19-3.13 (m, 1H), 2.81-2.75 (dd, J = 1.85, 6.05 Hz, 1H) 2.74-2.52 (dd, J = 1.9, 10.25 Hz, 1H), 2.17-1.84 (m, 1H), 1.85 -1.79 (m, 2H)

19F NMR 500MHz (CDCl3, δ ppm) 72.16(3F, S, OCF3) 19 F NMR 500 MHz (CDCl 3 , δ ppm) 72.16 (3F, S, OCF 3 )

본 발명에 따르면 4-하이드록시-2-피페리디논을 기존의 방법보다 온화한 반응조건에서 짧은 시간 내에, 간단하게 고순도 고수율로 경제적으로 얻을 수 있다.According to the present invention, 4-hydroxy-2-piperidinone can be economically obtained in a short time and simply in high purity and high yield under mild reaction conditions than conventional methods.

Claims (6)

하기 화학식 2의 베타케토 펜탄산 에스터를 루테늄 촉매 존재하에서 고압수소화 반응시켜 하기 화학식 3a 또는 3b의 베타 하이드록시 펜탄산 에스터를 합성한 후, 이를 탈보호 반응 및 고리화 반응시키는 단계를 포함하는, 하기 화학식 1a 또는 1b의 4-하이드록시-피페리디논의 제조방법:Comprising a high pressure hydrogenation of the beta keto pentanoic acid ester of the formula (2) in the presence of a ruthenium catalyst to synthesize the beta hydroxy pentanoic acid ester of the formula (3a) or 3b, and then deprotection and cyclization reaction, Process for preparing 4-hydroxy-piperidinone of formula 1a or 1b: <화학식 1a><Formula 1a>
Figure 112004032846012-PAT00014
Figure 112004032846012-PAT00014
<화학식 1b><Formula 1b>
Figure 112004032846012-PAT00015
Figure 112004032846012-PAT00015
<화학식 2><Formula 2>
Figure 112004032846012-PAT00016
Figure 112004032846012-PAT00016
<화학식 3a><Formula 3a>
Figure 112004032846012-PAT00017
Figure 112004032846012-PAT00017
<화학식 3b><Formula 3b>
Figure 112004032846012-PAT00018
Figure 112004032846012-PAT00018
상기 식에서,Where P 및 P1는 각각 독립적으로 벤질, 벤질옥시카보닐, t-부틸옥시카보닐, 벤조일 또는 아세틸을 나타내며, P and P 1 each independently represent benzyl, benzyloxycarbonyl, t-butyloxycarbonyl, benzoyl or acetyl, R은 탄소수 1 내지 4의 선형 또는 분지형 알킬기를 나타내고, R represents a linear or branched alkyl group having 1 to 4 carbon atoms, Q는 수소, 탄소수 1 내지 4의 선형 또는 분지형 알킬 또는 벤질을 나타낸다.Q represents hydrogen, linear or branched alkyl or benzyl having 1 to 4 carbon atoms.
제 1 항에 있어서,The method of claim 1, Q가 수소인 경우, 고리화 반응후 Pd/C 촉매 존재하에 상압에서 수소화 반응시키는 것을 추가로 포함함을 특징으로 하는 방법.And when Q is hydrogen, further comprising hydrogenating at atmospheric pressure in the presence of a Pd / C catalyst after the cyclization reaction. 제 1 항에 있어서,The method of claim 1, 루테늄 촉매가 (R)Ru2Cl4(BINAP)NEt3(디클로로[R(+)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄트리에틸아민),(S)Ru2Cl4(BINAP)NEt3(디클로로[S(-)-2,2'-비스( 디페닐포스피노)-1,1'-비나프틸]루테늄트리에틸아민), (R)Ru2Cl2(BINAP) 2(디클로로[R(+)-2,2'-비스(디페놀닐스피노)-1,1'-비나프틸]루테늄), (S)Ru2Cl2(BINAP)2 (디클로로[S(-)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸]루테늄), (R)Ru2Cl4(Tol-BINAP)2NEt3(디클로로[R(+)-2,2'-톨루일-비스(디페닐포스피노)-1,1'-비나프틸]루테늄트리에틸아민), 또는 (S)Ru2Cl4(Tol-BINAP)2NEt 3 (디클로로[S(-)-2,2'-톨루일-비스(디페닐스피노)-1,1'-비나프틸]루테늄트리에틸아민)임을 특징으로 하는 방법.Ruthenium catalyst is (R) Ru 2 Cl 4 (BINAP) NEt 3 (dichloro [R (+)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] rutheniumtriethylamine) , (S) Ru 2 Cl 4 (BINAP) NEt 3 (dichloro [S (-)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] rutheniumtriethylamine) , ( R) Ru 2 Cl 2 (BINAP) 2 (dichloro [R (+)-2,2'-bis (diphenolylspino) -1,1'-binafthyl] ruthenium), (S) Ru 2 Cl 2 (BINAP) 2 (dichloro [S (-)-2,2'-bis (diphenylphosphino) -1,1'-binafthyl] ruthenium), (R) Ru 2 Cl 4 (Tol-BINAP) 2 NEt 3 (dichloro [R (+)-2,2'-toluyl-bis (diphenylphosphino) -1,1'-binafthyl] rutheniumtriethylamine) , or (S) Ru 2 Cl 4 (Tol-BINAP) 2 NEt 3 (dichloro [S (-)-2,2'-toluyl-bis (diphenylspino) -1,1'-binafthyl] rutheniumtriethyl Amines). 제 1 항에 있어서,The method of claim 1, 수소화 반응이 테트라히드로푸란, 톨루엔, 벤젠, 아세토나이트릴, 디메틸포름아미드, 디메틸에테르, 에틸아세테이트 및 알코올로 이루어진 군중에서 선택된 1종 이상의 용매 중에서 수행됨을 특징으로 하는 방법.Wherein the hydrogenation reaction is carried out in one or more solvents selected from the group consisting of tetrahydrofuran, toluene, benzene, acetonitrile, dimethylformamide, dimethylether, ethyl acetate and alcohol. 제 1 항에 있어서,The method of claim 1, 탈보호 반응이 무기 또는 유기 산 촉매 존재하에 수행됨을 특징으로 하는 방법.The deprotection reaction is carried out in the presence of an inorganic or organic acid catalyst. 제 1 항에 있어서, The method of claim 1, 고리화 반응이 유기 또는 무기 염기 존재 하에 수행됨을 특징으로 하는 방법.The cyclization reaction is carried out in the presence of an organic or inorganic base.
KR1020040057706A 2004-07-23 2004-07-23 Process for preparation of chiral 4-hydroxy-2-piperidinone KR100574343B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020040057706A KR100574343B1 (en) 2004-07-23 2004-07-23 Process for preparation of chiral 4-hydroxy-2-piperidinone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040057706A KR100574343B1 (en) 2004-07-23 2004-07-23 Process for preparation of chiral 4-hydroxy-2-piperidinone

Publications (2)

Publication Number Publication Date
KR20060008051A true KR20060008051A (en) 2006-01-26
KR100574343B1 KR100574343B1 (en) 2006-04-27

Family

ID=37119202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040057706A KR100574343B1 (en) 2004-07-23 2004-07-23 Process for preparation of chiral 4-hydroxy-2-piperidinone

Country Status (1)

Country Link
KR (1) KR100574343B1 (en)

Also Published As

Publication number Publication date
KR100574343B1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
AU2019346118B2 (en) Manufacture of compounds and compositions for inhibiting the activity of SHP2
US20030225149A1 (en) Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US6809214B2 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
EP2189442A1 (en) Process and intermediates for the preparation of aliskiren
KR20100103646A (en) Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
US5276164A (en) Process for the production of 4-hydroxy-2-oxopyrrolidin-1-yl-acetamide
CN113636950B (en) Preparation method of chiral 4-aryl-beta-amino acid derivative
CN103288699A (en) Preparation method of proline analogue
KR100574343B1 (en) Process for preparation of chiral 4-hydroxy-2-piperidinone
KR100743617B1 (en) Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity
CN114409585A (en) 2-oxopyrrolidine derivatives, process for preparing the same and process for preparing intermediates
EP1926709A1 (en) Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity
KR100711938B1 (en) Method for preparing stereoselective 4-hydroxy-2-pyrrolidinone
KR101299720B1 (en) A novel process for preparing 3-amino-5-fluoro-4-dialkoxypetanoic acid ester
JP4491074B2 (en) Stereoselective process for producing nitroenamine compounds
KR100850558B1 (en) Process for preparing useful in synthesis of atorvastatin
US6632950B2 (en) Process for the preparation of derivatives of 4-amino-3-hydroxypyrrole-2-carboxylic acid
KR100532042B1 (en) Process for the preparation of n,n-substituted-7-amino-3,5-dihydroxy heptanoic acid derivatives
KR100896087B1 (en) Synthetic method of optically pure 2-methylpyrrolidine and the salt thereof
HU223138B1 (en) Novel process for producing alkyl-4,6,7,8,9,9a-hexahydro-2h,3h-pyrido[1,2-a]pyrazin-1-on-7-carboxylate esters
JP4187822B2 (en) Process for producing optically active 4-hydroxy-2-pyrrolidone
JP5576791B2 (en) Method for producing optically active amino acid derivative
KR100572409B1 (en) Method for preparing 4R-hydroxy-N-benzyl-2-piperidinone
JP2002212155A (en) Optically active asparagine ester derivative, optically active 3-aminopyrolidine-2,5-dione derivative and optically active 3-aminopyrrolidine derivative
WO2010048138A1 (en) Synthesis of intermediates useful for the production of certain cgrp inhibitors and intermediates used in such synthesis

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110411

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee